MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE

wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provide...

Full description

Saved in:
Bibliographic Details
Main Authors DAI, Yujia, KLING, Andreas, DOHERTY, George, LAI, Chunqiu, POHLKI, Frauke, SULLIVAN, Gerard, SOUERS, Andrew, TESKE, Jesse, JI, Cheng, JANTOS, Katja, Guillier, Fabrice, YU, Yiyun, ZHU, Guidong, PENNING, Thomas, JUDD, Andrew, KUNZER, Aaron, WENDT, Michael, RISI, Roberto, BRAJE, Wilfried, TAO, Zhi-Fu, BRADY, Patrick, WANG, Xilu, GONG, Jane, MASTRACCHIO, Anthony, SONG, Xiaohong, POTIN, Dominique
Format Patent
LanguageEnglish
Published 13.08.2020
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
Bibliography:Application Number: US201816639560